The FDA has created a formal regulatory category for a type of tumor marker that is injected as a liquid and changes into a solid inside the body, giving radiation oncologists a reference point for aiming treatment beams and giving future manufacturers a faster route to market.
The final order classifying the device type places the phase-changing fiducial marker for radiation therapy in class II with special controls, codified at 21 CFR 892.5727. The agency defines the device as a single-use, sterile liquid material that changes phase in situ when injected into tissue to aid radiation therapy, intended to be visualized using one or more imaging methods.
The order does not approve any new product and does not change treatment for anyone currently receiving radiation.
The Aiming Problem Radiation Oncology Has Always Had
Modern radiation therapy delivers high doses to a tumor while sparing surrounding tissue, and that precision depends entirely on knowing where the tumor is at the moment the beam turns on.
Tumors move. They shift with breathing, with bowel and bladder filling, and with day-to-day changes in patient positioning across a course of treatment that may run several weeks. Many soft-tissue tumors are also poorly visible on the imaging used at the treatment machine.
Fiducial markers solve this by providing a fixed, imageable reference. Small markers are placed in or near the tumor, and the treatment team aligns the beam to the markers rather than to a tumor they cannot clearly see. The markers do not track anything themselves. They hold still so the imaging system can find them.
Conventional markers are solid, typically gold seeds implanted through a needle. A liquid marker that solidifies after injection can be delivered through a smaller needle, which is part of why the approach has drawn clinical interest.
The Risks FDA Identified and How It Requires Them Managed
The classification sets out a specific list of hazards, and reading it is the clearest way to understand what can go wrong with a marker.
FDA identified adverse tissue reaction, infection, complications from implantation or marker migration, treatment delays caused by device malfunction or inability to locate the marker on imaging, interference with image-guided radiation therapy or with assessing how a tumor responded to treatment, and inaccurate radiation dose delivery from incorrect positioning or migration.
Marker migration is the central concern. A reference point that moves during a multi-week course of treatment is worse than no reference point, because the team may align confidently to the wrong location.
The special controls require clinical performance data evaluating migration risk through post-treatment follow-up, the ability to visualize the marker throughout treatment, whether the device interferes with tumor response assessment afterward, and all adverse events. Animal data must address toxicity and migration. Non-clinical data must show the marker maintains its physical form through treatment and follow-up, is visible on imaging, and does not interfere with radiation dose delivery. Additional requirements cover biocompatibility, sterility, shelf life, and usability testing. Labeling must describe the phase-change mechanism and the timeframe for reaching final state, and summarize adverse events from clinical testing.
The Pathway That Made This Possible
The regulatory mechanics here explain why a classification notice matters more than it appears to.
Any device not in commercial distribution before May 1976 is automatically placed in class III by operation of law, regardless of actual risk, and class III normally requires premarket approval. That is the most demanding pathway in device regulation.
The De Novo process exists to move genuinely novel but lower-risk devices out of that default. Nanovi A/S submitted a De Novo request for its BioXmark marker, and the FDA granted class II classification with special controls, clearing the device for use in radiographically marking lung, bladder, and lymph nodes in adults. The final order codifies that decision in the Code of Federal Regulations.
The downstream effect is the point. Once a device type is classified into class II through De Novo, it can serve as a predicate for future devices, so subsequent manufacturers can use the 510(k) premarket notification process instead of filing their own De Novo request or premarket approval application. FDA has not exempted this device type from 510(k) requirements, so premarket notification still applies.
What Patients Should and Should Not Take from This
This is a regulatory action, not a clinical advance, and the distinction is worth being precise about.
No new product was approved in this order. No efficacy claim was made. No survival benefit was demonstrated. Nothing in the order says this marker type performs better than conventional gold seeds, and FDA published no comparative outcome data.
Patients preparing for radiation therapy do not need to ask for this specific technology. Whether any fiducial marker is appropriate, and which type, depends on tumor site, imaging modality, treatment technique, and how the marker will be placed. Those are decisions for a radiation oncologist and the placing proceduralist.
A reasonable question for a patient beginning image-guided radiation therapy is simply whether markers will be used, how they would be placed, and what the placement procedure involves. Marker placement carries the risks of the procedure used to deliver it, which for endoscopic placement can include bleeding, infection, and pain.
What remains unknown is how widely this device type will be adopted, whether other manufacturers will now enter through the 510(k) pathway, and whether liquid markers offer measurable advantages over solid ones in routine practice.
Frequently Asked Questions
What is a fiducial marker? A small imageable object placed in or near a tumor to give the radiation team a fixed reference point for aiming treatment when the tumor itself is hard to see.
What makes this type different? It is injected as a liquid and changes phase into a solid inside the tissue, rather than being implanted as a preformed solid seed.
Did FDA approve a new product? No. The agency classified a device type and codified the special controls. No new product approval or efficacy claim accompanied the order.
What is the main risk? Marker migration. A reference point that shifts during treatment can lead to inaccurate dose delivery, which is why the special controls require migration data through post-treatment follow-up.
Does this change my radiation treatment? No. Nothing about current treatment changes. Whether markers are used, and which kind, is a clinical decision made by the radiation oncology team.
Why does class II matter? Novel devices default to class III, which requires premarket approval. Class II with special controls lets future manufacturers of similar devices use the lighter 510(k) pathway.
What should a patient starting radiation ask? Whether fiducial markers will be used, how they would be placed, what the placement procedure involves, and what its risks are.
